Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.
作者信息
Sivina Mariela, Kim Ekaterina, Wierda William G, Ferrajoli Alessandra, Jain Nitin, Thompson Philip, Kantarjian Hagop, Keating Michael, Burger Jan A
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
Blood. 2021 Dec 16;138(24):2589-2592. doi: 10.1182/blood.2021012315.
Abstract
摘要
相似文献
1
Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.依鲁替尼可使初治的慢性淋巴细胞白血病（CLL）且伴有17p缺失和/或TP53突变的患者获得持久缓解。
Blood. 2021 Dec 16;138(24):2589-2592. doi: 10.1182/blood.2021012315.
2
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.慢性淋巴细胞白血病：2017 年诊断、风险分层和治疗更新。
Am J Hematol. 2017 Sep;92(9):946-965. doi: 10.1002/ajh.24826.
3
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.苯达莫司汀和利妥昔单抗在未经治疗的先前不适合的慢性淋巴细胞白血病患者中的疗效。在真实环境中与伊布替尼的间接比较。一项 GIMEMA-ERIC 和美国的研究。
Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.
4
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.在伴有 TP53 缺失和/或突变的 CLL 患者中，联合靶向治疗后可获得持久缓解。
Blood. 2021 Nov 11;138(19):1805-1816. doi: 10.1182/blood.2020010484.
5
[Current diagnosis and treatment of chronic lymphocytic leukaemia].[慢性淋巴细胞白血病的当前诊断与治疗]
Dtsch Med Wochenschr. 2020 Aug;145(16):1139-1144. doi: 10.1055/a-1039-8472. Epub 2020 Aug 13.
6
Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived.2020 年的慢性淋巴细胞白血病：未来已至。
Curr Oncol Rep. 2020 Mar 14;22(4):36. doi: 10.1007/s11912-020-0893-0.
7
17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.17p 缺失强烈影响慢性淋巴细胞白血病中利妥昔单抗的清除。
J Immunother Cancer. 2019 Jan 29;7(1):22. doi: 10.1186/s40425-019-0509-0.
8
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.依鲁替尼和利妥昔单抗治疗的不适合的慢性淋巴细胞白血病患者的复杂核型：GIMEMA LLC1114 2期研究
Blood. 2021 Dec 23;138(25):2727-2730. doi: 10.1182/blood.2021011883.
9
TP53 mutation and survival in chronic lymphocytic leukemia.TP53 突变与慢性淋巴细胞白血病的生存。
J Clin Oncol. 2010 Oct 10;28(29):4473-9. doi: 10.1200/JCO.2009.27.8762. Epub 2010 Aug 9.
10
LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.LPL 缺失与基于伊布替尼治疗的反应较差和 TP53 缺失慢性淋巴细胞白血病的总生存期缩短相关。
Ann Hematol. 2020 Oct;99(10):2343-2349. doi: 10.1007/s00277-020-04223-y. Epub 2020 Aug 24.
引用本文的文献
1
Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment.慢性淋巴细胞白血病治疗现代 era 中的嵌合抗原受体 T 细胞
Cancers (Basel). 2025 Jan 15;17(2):268. doi: 10.3390/cancers17020268.
2
Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case report.利用李-弗劳梅尼综合征患者的体细胞致癌驱动基因改变——迈向精准医学之路：一例病例报告
J Cancer Res Clin Oncol. 2025 Jan 16;151(1):37. doi: 10.1007/s00432-024-06077-7.
3
Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment.慢性淋巴细胞白血病分子生物学的最新进展：如何定义预后并指导治疗
Cancers (Basel). 2024 Oct 14;16(20):3483. doi: 10.3390/cancers16203483.
4
BTK inhibitors in CLL: second-generation drugs and beyond.慢性淋巴细胞白血病中的 BTK 抑制剂：第二代药物及其他。
Blood Adv. 2024 May 14;8(9):2300-2309. doi: 10.1182/bloodadvances.2023012221.
5
Marginal zone lymphoma with severe rashes: A case report.伴有严重皮疹的边缘区淋巴瘤：一例报告。
World J Clin Cases. 2024 Jan 26;12(3):565-574. doi: 10.12998/wjcc.v12.i3.565.
6
Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.基于治疗和分子因素的加拿大大型集中性 CLL 临床十年预后分析。
Curr Oncol. 2023 Jul 5;30(7):6411-6431. doi: 10.3390/curroncol30070472.
7
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.治疗初治慢性淋巴细胞白血病的治疗方法选择中存在的未解决问题。
J Hematol Oncol. 2023 Jul 8;16(1):72. doi: 10.1186/s13045-023-01469-7.
8
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency.接受一线伊布替尼治疗的慢性淋巴细胞白血病伴 TP53 异常患者的结局：来自意大利药品管理局的全国注册研究。
Blood Cancer J. 2023 Jun 28;13(1):99. doi: 10.1038/s41408-023-00865-z.
9
Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.伊布替尼治疗慢性淋巴细胞白血病患者的真实世界临床结局和不良事件：一项单中心回顾性研究。
Medicina (Kaunas). 2023 Feb 9;59(2):324. doi: 10.3390/medicina59020324.
10
Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations.在慢性淋巴细胞白血病中选择最佳的布鲁顿酪氨酸激酶（BTK）抑制剂疗法：理论依据与实际考量
Ther Adv Hematol. 2022 Aug 9;13:20406207221116577. doi: 10.1177/20406207221116577. eCollection 2022.
本文引用的文献
1
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.维奈托克联合利妥昔单抗治疗复发慢性淋巴细胞白血病：III 期 MURANO 研究的 4 年结果和基因组复杂性及基因突变影响评估。
J Clin Oncol. 2020 Dec 1;38(34):4042-4054. doi: 10.1200/JCO.20.00948. Epub 2020 Sep 28.
2
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.维奈托克联合奥滨尤妥珠单抗与苯丁酸氮芥联合奥滨尤妥珠单抗治疗初治慢性淋巴细胞白血病（CLL14）：一项多中心、开放标签、随机、3 期临床试验的随访结果。
Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5.
3
Ibrutinib for Chronic Lymphocytic Leukemia with Alterations.伊布替尼用于治疗伴有改变的慢性淋巴细胞白血病。
N Engl J Med. 2020 Jul 30;383(5):498-500. doi: 10.1056/NEJMc2005943.
4
Treatment of Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病的治疗
N Engl J Med. 2020 Jul 30;383(5):460-473. doi: 10.1056/NEJMra1908213.
5
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.伊布替尼治疗一线和复发/难治性慢性淋巴细胞白血病：关键性 Ib/II 期 PCYC-1102 研究的最终分析。
Clin Cancer Res. 2020 Aug 1;26(15):3918-3927. doi: 10.1158/1078-0432.CCR-19-2856. Epub 2020 Mar 24.
6
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.RESONATE-2 研究 5 年随访：伊布替尼一线治疗 CLL/SLL 患者的长期疗效和安全性。
Leukemia. 2020 Mar;34(3):787-798. doi: 10.1038/s41375-019-0602-x. Epub 2019 Oct 18.
7
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.伊布替尼联合利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的比较
N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.
8
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.随机对照试验：伊布替尼对比伊布替尼联合利妥昔单抗治疗慢性淋巴细胞白血病患者。
Blood. 2019 Mar 7;133(10):1011-1019. doi: 10.1182/blood-2018-10-879429. Epub 2018 Dec 7.
9
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.伊布替尼方案与化疗免疫治疗在未经治疗的老年 CLL 患者中的比较。
N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.
10
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.初治 CLL 患者采用 FCR 化免治疗后的长期缓解：CLL8 试验的更新结果。
Blood. 2016 Jan 14;127(2):208-15. doi: 10.1182/blood-2015-06-651125. Epub 2015 Oct 20.
Zotero 插件